Literature DB >> 11791658

Matrix metalloproteinase 9 (MMP-9) in patients with psoriatic arthritis and rheumatoid arthritis.

G M Alenius, S Jonsson, S Wållberg Jonsson, A Ny, S Rantapää Dahlqvist.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11791658

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  5 in total

1.  Expression and distribution of matrix metalloproteinases and their inhibitors in the human iris and ciliary body.

Authors:  J Lan; R K Kumar; N Di Girolamo; P McCluskey; D Wakefield
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

2.  Interleukin-1alpha-induced proteolytic activation of metalloproteinase-9 by human skin.

Authors:  Yuan-Ping Han; Susan Downey; Warren L Garner
Journal:  Surgery       Date:  2005-11       Impact factor: 3.982

Review 3.  TRPV4 as a therapeutic target for joint diseases.

Authors:  Amy L McNulty; Holly A Leddy; Wolfgang Liedtke; Farshid Guilak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-12-18       Impact factor: 3.000

4.  Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha.

Authors:  Paola Cordiali-Fei; Elisabetta Trento; Giovanna D'Agosto; Valentina Bordignon; Anna Mussi; Marco Ardigò; Antonio Mastroianni; Antonella Vento; Francesco Solivetti; Enzo Berardesca; Fabrizio Ensoli
Journal:  J Autoimmune Dis       Date:  2006-10-05

5.  Differences in Osteoimmunological Biomarkers Predictive of Psoriatic Arthritis among a Large Italian Cohort of Psoriatic Patients.

Authors:  Marco Diani; Silvia Perego; Veronica Sansoni; Lucrezia Bertino; Marta Gomarasca; Martina Faraldi; Paolo Daniele Maria Pigatto; Giovanni Damiani; Giuseppe Banfi; Gianfranco Altomare; Giovanni Lombardi
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.